Pathologists (CAP) suggested that LVI should be reported in the routine examination of RP specimens in the 2010 consensus statement, there is a lack of convincing evidence to support its prognostic value. 8 Therefore, we conducted a systematic review of current publications to assess the prognostic value of LVI in BCR, and a meta-analysis was performed for the extracted data that could be merged.
INTRODUCTION
Prostate cancer (PCa) is the second most common cancer and the sixth leading cause of cancer-related death in Caucasian men, and there were estimated 238 590 new PCa cases and 29 720 deaths from PCa in the United States in 2014. 1 With advances in the minimally invasive technologies, radical prostatectomy (RP) as the standard treatment has made great progress in improving perioperative outcomes. Nevertheless, early biochemical recurrence (BCR) occurred in approximately 20% patients undergoing RP, 2,3 in whom the 5-year metastasis rate was as high as 30%-44%. 4 Thus, it is imperative for clinicians to identify risk factors of post-RP BCR, and provide advisable indexes for adjuvant therapies including external beam radiotherapy (EBRT), intensity-modulated radiotherapy, and androgen deprivation therapy.
To date, although some potential biomarkers including Lymphovascular Invasion (LVI) have been added to the pathological reports of PCa patients who underwent prostatectomy, their impact on prognosis such as BCR has not been sufficiently evaluated.
5 LVI has been documented as a poor prognostic factor in many solid tumors. 6 ,7 Some authors have demonstrated an association between the presence of LVI in prostatectomy specimens and BCR. Although the College of American
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Data extraction
The following specified data were gathered from each eligible study: (1) main characteristics including the author, country, publication year, institution, recruitment period, study design, pathology stain method, definition of LVI, definition of BCR, the number of patients, median age at operation, the number of pelvic lymph node dissection (PLND), neoadjuvant (neo), androgen deprivation therapy (ADT), external beam radiotherapy (EBRT), and median follow-up time (Supplementary  Table 1) ; (2) Tumor-Node-Metastasis (TNM) stage characteristics, Gleason score, and correlation between LVI and preoperative PSA and pathological parameters (Supplementary Table 2) ; (3) HR of LVI in univariate or multivariate Cox analyses, Co-factors, and the conclusion of each study concerning whether LVI was an independent predictor (Supplementary Table 3 ).
Statistical analysis
The primary objective of this review was to determine differences in survival outcomes between patients with negative LVI and positive LVI. HR and 95% CI were collected from each study if they were not directly reported, and the HR was estimated according to the method reported by Tierney et al. 9 The overall pooled HR was estimated by calculating the weighted average of the log-HRs and their 95% CI from each study. An observed HR >1 implied a poor survival outcome for patients with positive LVI. The impact of LVI on the outcome was considered as an independent predictor if the 95% CI did not overlap with 1 and P < 0.05. Subgroup analysis was performed to check whether the pooled HR was influenced by the region and number of patients, pathologic N stage, median follow-up, analysis results, definition of BCR, staining method, and staging system. In order to assess the stability of the combined HR, sensitivity analysis was performed by removing one study. The heterogeneity of the combined HR was evaluated using the Chi-square ( 2 test) and inconsistency (I 2 test). Meta-analysis used the fixed-effect model,
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when P ≥ 0.1 and I 2 ≤ 50%, which indicated a moderate heterogeneity between studies, 11 whereas when P < 0.1 or I 2 > 50%, which indicated large heterogeneity, 11 the random-effect model was applied. 12 In addition, publication bias was evaluated by Egger's linear regression and Begg's rank correlation.
The secondary objective of this review was to study the relationship between the pathological parameters of PCA and LVI. The data of pathological stage were divided as low-stage (pT2) group and high stage (pT3-4) group. Gleason scores were categorized as low Gleason score (GS <7) and high Gleason score (GS ≥7). The RR of the high stage or high Gleason score along with the corresponding 95% CI was calculated by meta-analysis. In addition, the extracapsular extension (ECE), seminal vesicle involvement (SVI), and pathological node (pN) were directly divided as positive and negative. RR and CI of positive components were analyzed. Stata (Version 12.0; Stata Corp, College station, TX, USA) was used for all statistical analyses.
RESULTS
A total of 25 studies were selected for the systematic review and meta-analysis (Figure 1) . With regard to the primary objective, survival outcomes with negative LVI and positive LVI were evaluated. Some studies revealed that LVI was an independent predictor in cancer-specific survival (CSS), 13,20 distant metastasis (DM), 13, 22 progression-free survival (PFS), 29 overall survival (OS), 13 and these details are shown in Supplementary Table 3, however, the data for CSS, DM, PFS, OS were not available in any study. Nevertheless, 21 studies provided the BCR data, and the meta-analysis showed that positive LVI was correlated with poorer BCR in RP patients (HR = 2.05, 95% CI, 1.64-2.56, P < 0.00001) (Figure 2) . Test of Cochrane Q ( 2 = 47.39, P = 0.001) and inconsistency test (I 2 = 57.8%) could not exclude a significant heterogeneity. Given the large heterogeneity between the studies, subgroup analysis was performed, and the results are shown in Supplementary Table 4 . In sensitivity analysis, one-way sensitivity analysis was carried out to exclude a single study and calculated the pooled HR for remaining studies, and omission of each study did not have a significant impact on the merged value of HR. Allowing for publication bias, Begg's funnel plot was performed, and no significant publication bias was detected between these studies regarding HR of BCR with P = 0.112. In addition, Egger's test (P = 0.207) demonstrated a similar result (Figure 3) . The secondary objective was to assess the relationship between LVI and higher pathological tumor stages (> pT3 stage), higher Gleason score (>GS = 7), positive pN, ECE and SVI. Ten studies provided data on the number of higher pT stage in the positive LVI groups and negative LVI groups, and the pooled RR was 1.90 (95% CI, 1.73-2.08; Z = 13.45, P < 0.00001) with a moderate heterogeneity (P = 0.054 for heterogeneity; I 2 = 46.1%) (Figure 4a) . Similarly, the data of other pathological parameters were extracted from eligible studies, and we found that LVI was significantly correlated with higher GS (pooled RR, 1.30; 95% CI, 1.23-1.39; Z = 8.55, P < 0.00001) with a moderate heterogeneity (P = 0.019 for heterogeneity; I 2 = 47.1%) (Figure 4b ), positive pN status (pooled RR, 5.67; 95% CI, 3.14-10.24; Z = 5.74, P < 0.00001) with a large heterogeneity (P < 0.00001 for heterogeneity test; I 2 = 72.8%) (Figure 4c ), ECE (pooled RR, 1.72; 95% CI, 1.46-2.02; Z = 6.50, P < 0.00001) with a large heterogeneity (P < 0.00001 for heterogeneity test; I 2 = 73.6%) (Figure 4d ) and SVI (pooled RR, 3.36; 95% CI, 2.41-4.70; Z = 7.11, P < 0.00001) (Figure 4e ) despite a large heterogeneity among studies (P < 0.00001 for heterogeneity test; I 2 = 81.9%).
DISCUSSION
Lymphovascular invasion is defined as the presence of a tumor within an endothelial-lined space, 8 which most probably links with the hematogenous spread of tumor cells. Tumor cells first infiltrate into lymphatic and/or vascular vessels, and then disseminate, 38, 39 which is a much more common phenomenon in malignant tumors including PCA. 40 In addition, LVI is a significant prognostic factor in bladder, upper urinary tract urothelial and lung cancers, which has been confirmed in several systematic review studies. [41] [42] [43] As regards to liver and testicular tumors, LVI has been added to the TNM staging system, in terms of improved tumor staging. 44, 45 Although the prognostic value of LVI in PCA patients after RP has been appraised by a number of studies, the results remain controversial.
The results obtained in our meta-analysis are in line with those in a previous System Review by Ng et al . 46 In addition, our study presented a series of advancements in comparison with the previous studies. First, we included more eligible studies with large sample sizes. The Ng's search time was ended in 2009. However, we added 8 extra studies including 2825 patients from 2009 to 2014, thus providing more exact evaluation on the effect and enabling more authentic subgroup analyses. Second, although the same result was obtained in Ng's study reporting a significant relationship between LVI and BCR in RP, we found that the pooled result of LVI had a large heterogeneity (I 2 = 57.8%) by meta-analysis, and so we conducted a subgroup analysis. Meanwhile, the sensitivity analysis of our study revealed that the omission of each study did not have a significant impact on the merged value of HR. In contrast, Ng et al. 46 only assessed the quality of publications and no other analysis on the reliability of the result was done.
In our subgroup analyses of the region, sample size, pN status, follow-up time, negative/positive result of LVI, PSA level definition of BCR and staining method, we found a significant correlation between LVI and poor BCR. Notably, in large sample groups with the number of patients larger than 500, the pooled HR was 1.58 (1.28-1.95). In the short-term follow-up group with the follow-up duration <24 months, we also found that LVI could serve as a predictor in early BCR and be used in Nomogram for predicting BCR. 47 Although only one study 34 revealed that the addition of LVI only marginally improved the predictive accuracy (from 0.880 to 0.884). In addition, LVI was correlated with higher pT stages, higher GS, positive pN status, ECE, and SVI, indicating that the presence of LVI in PCa may predict the higher risk of progression with poor BCR, PFS, CSS, DM, and OS, and some previous studies 13, 20, 22, 29 may support this possibility though we do not have available data to further analysis. There are some limitations in our meta-analysis. The first is the problem of heterogeneity due to relevant baseline patient characteristics of each study. Although we took into account the heterogeneity in our meta-analysis using the random-effects model, the conclusion drawn in this study should be considered prudently. Second, as some of the studies were unable to provide data available to calculate HRs of BCR, we could not merge their results, although publication bias evaluation of BCR showed no significant difference and sensitivity analysis confirmed the prognostic value of LVI. In addition, as only few included studies covered survival outcomes such as PFS, CSS, DM, and OS, we were unable to perform a meta-analysis for the lack of data available to calculate HR and 95% CI directly or indirectly. Finally, most studies were retrospective, and only two studies included in our meta-analysis were prospective. Therefore, more prospective multicenter trials are required to confirm the conclusion.
In addition to these study limitation, it is usually difficult to completely exclude subjective bias among pathologists in clinical practice. 8 Knowing that the surrounding stromal tissue can mimic vascular invasion that cannot be easily be recognized, experts have reached agreement that the report of LVI is only in unequivocal cases.
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With regard to staining method, hematoxylin and eosin (HE) is the most commonly used examination for LVI. However, some included studies incorporated immunohistochemical analysis, and this added measure may increase the detection rate of LVI. 26 But as there are still controversies over the use of immunohistochemical analysis, it is not used routinely in clinical practice. What's more, in most studies, tumor cells invasion in lymphatic vessels and vascular vessels were combined as LVI and no effort was made to distinguish between them. One reason for this is the difficulty that there is lack of reproducibility when using routine light microscopy, and previous studies have not fully evaluated the clinical values to assess the survival outcomes of prostate cancer in terms of distinguishing vascular invasion from lymphatic invasion.
CONCLUSION
Our meta-analysis indicates that LVI has a detrimental effect on the BCR-Free probability, and clinicopathological features in RP specimens and, therefore, could be considered as an independent prognostic factor of BCR. It could also be used to predict BCR patients who need further adjuvant therapies.
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